Pharmspot
Your faithful ally when landing a new pharma market
Pharmspot covers critical pieces of info needed for a medicine market entry decision, including:drug approval, intellectual property, and exclusivities.
01 Reliability
Reliable drug patent linkage
Pharmspot includes drugs approved by the US-FDA and JP-PMDA and adds the patents linked to each drug as well as accurate expiry dates for every patent. The reliability of the linkage enables pharma companies, especially generics, to quickly understand if and when they could enter a new market.
02 Coverage
Core patent coverage
Pharmspot includes 9,200+ core patents and 200,000 family members, relevant to 25400+ drugs approved in the U.S. and Japan. The coverage of core drug patents allows users to more efficiently assess the legal risks associated with market entry and track legal status changes of out.
03 Edge
Purple Book patent data
Distinct from Orange Book (FDA-approved chemical rugs) which includes patents, Purple Book (FDA-approved biological drugs) is missing patent data. While regulations have been modified to require the submission of patents exchanged in "Patent Dance", the number of involved drugs and patents is limited. Pharmspot’s Purple Book patent data goes far beyond this, making it especially useful for companies looking to expand their product portfolio in the US market for biological/biosimilar drugs.
Our Offerings
Our flexible delivery methods allow you to maximize the value of the data.
SaaS platform
The subscription-based platform allows users to access critical patent and exclusivity data and insights about a drug through a simple query, enabling them to strategize and navigate the complex landscape of pharmaceutical intellectual property faster while reducing costs.
Bulk Data
The data set, consisting of backfiles and updates, can be easily integrated into any industry database that has certain drug data or patent data but not the type/quality of metadata we offer, thereby empowering the search & analytics capabilities of such a database.
Consulting
Through our consulting engagements, we provide customized solutions and expert insights to meet specific customer needs. The engagements may entail providing deeper analysis and interpretation of existing drug patents or conducting a thorough patent review and assessment.
Latest News
About Us
IPDataLab is a technology company focused on enhancing the accessibility and utility of patent information. Positioned at the intersection of patent data and software management, our mission is to link individual patents to indicators of corresponding commercial activity. As a separate entity from IPDataLab USA, IPDataLab Canada focuses on the pharmaceutical sector and is responsible for Pharmspot.
CEO & Co-Founder
Miao Li
With 16+ years of experience as a patent attorney and software product manager, Miao brings a wealth of knowledge and expertise to the company. Before IPDataLab, she was the product management leader for a global patent search product at LexisNexis, leading project teams with 60+ members. During her early career, Ms. Li was a patent attorney at Procter & Gamble. She has a technical background of Materials Engineering and deep knowledge about pharmaceutical patents. She once translated book Protecting and Enforcing Life Science Inventions in Europe: under EPC and EU Law, published by IPPH in 2020.
Co-Founder
Chris Holt
With the background in patent analytics and business development, Chris brings invaluable industry insights and strategic vision to IPDataLab. Chris has 20+ years of experience as a patent and trademark attorney, with expertise in managing both U.S. and foreign portfolios. He’s recognized as a pioneer in data-driven management of intellectual property assets: the patent examiner analytics tool PatentCore (sold to LexisNexis in 2014) he founded was the first ever SAAS tool providing comprehensive statistical insight into decision-making patterns demonstrated by patent examiners. He assumed the role of Vice President of Patent Analytics for LexisNexis IP between 2014 and 2019.
Co-Founder
Ulrike Biedermann
Ulrike brings extensive experience in sales and business development to the team. With a Master of Business Administration degree and a focus on information, knowledge, and data management, Ulrike has a proven track record of selling complex solutions and products in need of explanation. Prior to joining IPDataLab, Ulrike headed up the European sales team of LexisNexis IP, where she was responsible for the IP product portfolio. Her expertise in sales and strategic planning enhances IPDataLab's ability to drive revenue growth and expand its market presence.